Company intelligence / Profile preview

Tera Science

Changwon, Gyeongsangnam-do, South Korea

Ownership: Private
Employees: ~60
Development stage: Other

Overview

Tera Science is a South Korean company, originally focused on industrial hydraulic components, that has diversified into the life sciences and renewable energy sectors. Through its subsidiary and investments, most notably in the U.S.-based biotech firm OncoPep, the company is involved in the development of targeted cancer immunotherapies. Its lead asset, PVX-410, is a therapeutic cancer vaccine being evaluated for indications such as multiple myeloma and breast cancer. Tera Science is publicly traded on the KOSDAQ exchange and continues to expand its footprint in the global healthcare market through strategic acquisitions and R&D investments.

Therapeutic areas: Oncology
Modalities: VaccinePeptides
Industry: Biotech

Partnerships

Dana-Farber Cancer Institute

Beyond the preview

Go deeper on Tera Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tera Science.

Explore the full profile